Sangamo Therapeutics, Inc. (NASDAQ:SGMO)‘s stock had its “hold” rating restated by research analysts at Wedbush in a report released on Wednesday. They currently have a $6.00 price objective on the biopharmaceutical company’s stock. Wedbush’s target price would suggest a potential downside of 59.04% from the company’s previous close.

Other equities analysts have also recently issued reports about the stock. Zacks Investment Research raised shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a research note on Wednesday. Piper Jaffray Companies raised shares of Sangamo Therapeutics from a “neutral” rating to an “overweight” rating and set a $19.00 target price for the company in a research note on Wednesday. ValuEngine raised shares of Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, August 11th. BidaskClub cut shares of Sangamo Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 5th. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $18.00 target price on shares of Sangamo Therapeutics in a research note on Thursday, September 14th. One analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. Sangamo Therapeutics has an average rating of “Buy” and a consensus price target of $17.40.

Sangamo Therapeutics (NASDAQ SGMO) traded up $1.75 during midday trading on Wednesday, hitting $14.65. 3,654,400 shares of the stock were exchanged, compared to its average volume of 1,297,629. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.64 and a current ratio of 5.64. Sangamo Therapeutics has a 12 month low of $2.65 and a 12 month high of $17.06.

Sangamo Therapeutics (NASDAQ:SGMO) last released its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.04. Sangamo Therapeutics had a negative net margin of 157.66% and a negative return on equity of 31.81%. The business had revenue of $11.81 million during the quarter, compared to analysts’ expectations of $10.37 million. During the same period last year, the business earned ($0.27) earnings per share. The firm’s revenue was up 333.0% on a year-over-year basis. analysts predict that Sangamo Therapeutics will post -0.84 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Wedbush Reiterates Hold Rating for Sangamo Therapeutics, Inc. (SGMO)” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/11/15/wedbush-reiterates-hold-rating-for-sangamo-therapeutics-inc-sgmo.html.

In other Sangamo Therapeutics news, VP Curt A. Herberts III sold 15,000 shares of Sangamo Therapeutics stock in a transaction on Friday, September 1st. The shares were sold at an average price of $15.00, for a total transaction of $225,000.00. Following the completion of the transaction, the vice president now directly owns 15,833 shares of the company’s stock, valued at $237,495. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director William R. Ringo sold 31,000 shares of Sangamo Therapeutics stock in a transaction on Wednesday, September 20th. The stock was sold at an average price of $14.37, for a total transaction of $445,470.00. Following the transaction, the director now directly owns 31,800 shares of the company’s stock, valued at $456,966. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 61,000 shares of company stock valued at $899,220. Company insiders own 5.50% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in SGMO. Bank of New York Mellon Corp boosted its position in Sangamo Therapeutics by 6.1% during the first quarter. Bank of New York Mellon Corp now owns 333,305 shares of the biopharmaceutical company’s stock worth $1,732,000 after purchasing an additional 19,142 shares during the period. Parametric Portfolio Associates LLC acquired a new stake in shares of Sangamo Therapeutics during the first quarter worth $578,000. American International Group Inc. lifted its holdings in shares of Sangamo Therapeutics by 7.1% during the first quarter. American International Group Inc. now owns 42,747 shares of the biopharmaceutical company’s stock worth $222,000 after buying an additional 2,818 shares in the last quarter. Teachers Advisors LLC lifted its holdings in shares of Sangamo Therapeutics by 9.8% during the first quarter. Teachers Advisors LLC now owns 180,858 shares of the biopharmaceutical company’s stock worth $940,000 after buying an additional 16,130 shares in the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of Sangamo Therapeutics by 8.4% during the first quarter. Vanguard Group Inc. now owns 3,087,650 shares of the biopharmaceutical company’s stock worth $16,056,000 after buying an additional 239,544 shares in the last quarter. 64.08% of the stock is owned by hedge funds and other institutional investors.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Analyst Recommendations for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.